Categories AlphaGraphs, Earnings, Health Care
ABBV Infographic: AbbVie’s Q3 earnings beat estimates; revenue up 3%
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a sharp increase in third-quarter adjusted earnings. The bottom line topped expectations, while revenues missed. The company also provided guidance for fiscal 2022.
Total revenues increased 3.3% year-over-year to $14.81 billion, aided by a strong performance by the immunology and neuroscience segments. But the top line missed the Street view.
At $3.66 per share, adjusted net income was sharply higher than the $2.83 per share profit reported in the prior-year period, and above the consensus forecast. Third-quarter unadjusted profit increased to $3.95 billion or $2.21 per share from $3.18 billion or $1.78 per share in the third quarter of 2021.
Check this space to read management/analysts’ comments on AbbVie’s Q3 2022 earnings
“We continue to see strong momentum from our key immunology assets, Skyrizi and Rinvoq, and this performance – combined with strength from other growth drivers within our diverse portfolio – has mitigated the impact of temporary economic headwinds on our aesthetics products to deliver another quarter of strong results,” said Richard A. Gonzalez, CEO of AbbVie.
Prior Performance
Most Popular
Infographic: Key metrics from Estee Lauder’s (EL) Q3 2024 earnings results
The Estee Lauder Companies Inc. (NYSE: EL) reported its third quarter 2024 earnings results today. Net sales were $3.94 billion, up 5% from the prior-year quarter. Organic sales increased 6%.
YUM Earnings: Key quarterly highlights from Yum! Brands’ Q1 2024 financial results
Yum! Brands, Inc. (NYSE: YUM) reported first quarter 2024 earnings results today. Total revenues decreased 3% year-over-year to $1.59 billion. Same-store sales declined 3%. Net income increased 5% to $314
Pfizer (PFE) Q1 2024 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported first quarter 2024 earnings results today. Revenues decreased 20% year-over-year to $14.8 billion. Reported net income declined 44% to $3.1 billion, or $0.55 per share,